Meiji Seika Pharma Co., Ltd.

Meui Seika Kaisha, Ltd.

Naoko Watanabe

Takashi Yaguchi

Takeru Yamakawa

Yuji Tabata

Fumikazu Yokoyama

Chika Kikuchi

Takashi Matsuhira

Goh Tsujiuchi

Nobuaki Kushida

Kaori Kaneda

Natsuki Kubota

Takako Okuda

Provided is a compound represented by formula (1a) or a pharmacologically acceptable salt thereof, which can be used as a phosphodiesterase (PDE) inhibitor. Rto Rin the formula each independently represent an alkyl group or the like. 

PDE4 inhibitor

This invention provides novel PF1270A substance, PF1270B substance and PF1270C substance represented by the following formula (1) or pharmaceutically acceptable salts thereof, a method for producing the same and a pharmaceutical composition which comprises at least one of the same as the active ingredient. Since a group of the PF1270 substances of the invention show high affinity for histamine Hreceptor, they are expected as novel histamine Hreceptor ligands useful as medicaments. 

Physiologically active substances PF1270A, B and C substances

Growing community of inventors

Yokohama, Japan

Naoko Watanabe